Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Consistent Efforts to Find Effective Drugs is Driving Growth of Multiple Sclerosis Drugs Market to Valuation of ~US$ 32 bn by 2027, Finds TMR

- In the US alone, the number of people suffering from the disease is more than 1 million, whereas the global numbers are around 2.3 million people

- Naturally, the primary onus of the market stakeholders to prioritize development of new drugs with higher efficiency and minimal side effects

This image opens in the lightbox

News provided by

Transparency Market Research

13 Feb, 2020, 08:39 GMT

Share this article

Share toX

Share this article

Share toX

ALBANY, New York, Feb. 13, 2020 /PRNewswire/ -- Transparency Market Research has been keen following the developments happening across the global Multiple Sclerosis Drugs Market. According to the research report published by TMR, the market is expected to exhibit a healthy CAGR of ~6% for the given period of forecast ranging from 2019 to 2027. With this rate of development, the global market for multiple sclerosis drugs is expected to reach a valuation worth ~US$31.5 bn by the end of 2027. In 2019, the market was valued ~US$20 bn.

In recent years, there has been a strong prevalence of multiple sclerosis. This factor coupled with growing geriatric population across key regional segments, and growing awareness about the disease are a few factors that are helping to drive the development of the global multiple sclerosis drugs market.

Key Findings in the Research Report:

  • The global market for multiple sclerosis is broadly divided in terms of disease type, route of administration, distribution channel, drug class, and region
  • Based on type of disease, the market is further segmented into progressive-relapsing MS (PRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and relapsing-remitting MS (RRMS). The segment of RRMS is expected to dominate the global market in coming years
  • In terms of route of administration, the multiple sclerosis drugs market is being dominated by the sub-segment of parenteral route of administration. The segment is expected to have a promising CAGR due to the fact that nearly 75% to 85% of patients suffering from RRMS
  • Of the different types of distribution channel such as online pharmacies and hospital pharmacies, the segment of retail pharmacies & drug stores is projected to have a more promising rate of growth
  • In terms of drugs class, the interferon beta segment accounted for a larger market share in 2018. However, the segment of monoclonal antibodies is expected to emerge as a stronger drug class segment in the near future.

Explore a 207 pages report with detailed research, incisive insights, and in-depth country levels estimations. Gain business intelligence on global Multiple Sclerosis Drugs Market by Drug Class: Interferon Beta, Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, NF-KB Inhibitor, Pyrimidine Synthesis Inhibitor, Monoclonal Antibodies, Corticosteroids, Adrenocorticotropic Hormone, and Others; Disease Type: Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS), Secondary-progressive MS (SPMS), and Progressive-relapsing MS (PRMS); Route of Administration: Parenteral and Oral; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies https://www.transparencymarketresearch.com/report-toc/1130

Global Multiple Sclerosis Drugs Market – Key Driving Factors

  • One of the major driving factors for the development of the global multiple sclerosis drugs market is the considerable growth in the number of projects focusing on research and development of new treatment methods for tackling the disease
  • The key stakeholders in the market are pouring in significant amount of investment for development of new drugs with improved efficiency and minimal side effects. Funding from both private as well as public sector is beneficial for the overall development of the global market
  • In recent years, the new medications have been able to slow down the spread and effect of multiple sclerosis. With increasing awareness about the new treatment methods, the market is experiencing a solid impetus in recent years, thus driving its overall growth

Global Multiple Sclerosis Drugs Market – Key Restraining Factors

Even though the market is developing at a great pace, there are a few factors that are expected create some challenges in future. The key stakeholders in the global multiple sclerosis drugs market must be aware of these challenges and be ready with viable solutions to minimize their effect. One big concern for the market has been the lack of treatment method or drugs that can completely cure multiple sclerosis. Though the efforts of the all the research and development activities are focused on development of such drugs, the slowness of the process may pose a problem for the overall growth of the market.

Download a PDF Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1130

Global Multiple Sclerosis Drugs Market – Regional Outlook

  • Of the different regional segments of the global multiple sclerosis drugs market, the region of North America accounts for a dominant share. The growth of the regional market is driven by the favorable reimbursement policies and presence of a robust medical infrastructure. Furthermore, increasing prevalence of disease and early availability new drugs are some of the other key growth factors for the region
  • Asia Pacific segment is expected to show a promising rate of growth in the near future. Emerging economies such as India and China are expected to invest in development of their domestic healthcare infrastructure which will be likely to help the growth of the multiple sclerosis drugs market in the region

Analyze Multiple Sclerosis Drugs market growth in 30+ countries including US, Canada, Germany, United Kingdom, France, Italy, Russia, Poland, Benelux, Nordic, China, Japan, India, and South Korea. Request a sample of the study.

Global Multiple Sclerosis Drugs Market – Competitive Landscape

There are numerous notable brands operating in the global multiple sclerosis drugs market. These companies in the market are expected to focus on inorganic growth strategies such as acquisitions and mergers for staying competent in the global market. With increasing onus on development of newer and more effective drugs, the companies are expected invest more in the research and development activities in coming years of the forecast period.

Some of the prominent brands in the global multiple sclerosis drugs market are Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), and AbbVie, Inc.

Global Multiple Sclerosis Drugs Market: Segmentation

  • Multiple Sclerosis Drugs Market, by Drug Class
    • Interferon Beta
    • Sphingosine 1 Phosphate Receptor Modulators
    • Mixed Polymers
    • NF-κB Inhibitor
    • Pyrimidine Synthesis Inhibitor
    • Monoclonal Antibodies
    • Corticosteroids
    • Adrenocorticotropic Hormone
    • Others
  • Multiple Sclerosis Drugs Market, by Disease Type
    • Relapsing-remitting MS (RRMS)
    • Primary-progressive MS (PPMS)
    • o  Secondary-progressive MS (SPMS)
    • Progressive-relapsing MS (PRMS)
  • Multiple Sclerosis Drugs Market, by Route of Administration
    • Parenteral
    • Oral
  • Multiple Sclerosis Drugs Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies & Drug Stores
    • Online Pharmacies
  • Multiple Sclerosis Drugs Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of the Europe
    • Asia Pacific  
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

Explore Transparency Market Research's award-winning coverage of the global Healthcare industry:

Monoclonal Antibodies Market  - Driving the growth of the global monoclonal antibodies market is the increasing prevalence of cancer and other chronic diseases. Such maladies have resulted in soaring demand for biologics, which in turn is leading to the demand for monoclonal antibodies. Rising thrust on research and development activities in genomics alongside the emergence of technologically advanced genetic platforms, such as next generation sequencing, have also majorly contributed to the market. 

Corticosteroids Market - Factors driving the growth of the global corticosteroids market include growing geriatric population, increasing incidence of chronic diseases, rising demand for topical corticosteroids, and surging investment in research and development. Companies are increasingly participating in mergers and acquisitions to strengthen their position in the market.

Medical Aesthetic Devices Market - Health concerns and rise in demand for technologically advanced products boost the growth of the global medical aesthetic devices market. The global market is estimated at US$ 7,798.20 Mn in 2017 and is projected to expand at a CAGR of 10.7% from 2018 to 2026.

Hormone Replacement Therapy Market - The rising incidences of hormonal imbalance disorders and increasing geriatric population as well as the neonatal population suffering from hormonal deficiency are the primary drivers of this market. Technological advancements in the field of drug delivery systems, presence of routinely monitored formulations, and increasing awareness among the consumers are others factors favoring the growth rate of the market. 

Neurorehabilitation Devices Market - The novel approach of electric stimulation of the spinal cord has been receiving attention in recent years. This is evident since the brain & spinal cord injury application segment is predicted for exponential growth in the market for neurorehabilitation devices. The global neurorehabilitation devices market is estimated to reach a revenue of ~US$ 3.2 Bn by the end of 2027.

Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."

Contact

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com 
Website: http://www.transparencymarketresearch.com

Logo: https://mma.prnewswire.com/media/1085206/Transparency_Market_Research_Logo.jpg

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.